In-silico Study of Epicathecin from Cinnamomum verum Against Insulin Receptor for Diabetes Mellitus

Abstract

Obesity has become more common in recent years. Fatalism can raise the chance of fatal metabolic and cardiovascular diseases. Type 2 diabetes is one of the metabolic illnesses brought on by fat. Insulin receptor resistance, also known as non-insulin dependent type 2 diabetes, is a consequence of type 2 diabetes. Reduced insulin sensitivity and the inability of pancreatic beta cells to produce enough insulin to offset the development of resistance are the main causes of type 2 diabetes mellitus. Insulin receptor problems that decrease INSR expression on the cell surface and follow receptor abnormalities are the common mechanisms behind insulin receptor resistance. The single-nucleotide found in INSR. Increasing the expression of 4IBM is one strategy to combat its effects on insulin receptor function and increased risk of INSR-mediated illnesses. Based on earlier studies, cinnamon (Cinnamomum verum), a traditional plant, has been shown to have potential as a treatment for a number of illnesses, including diabetes mellitus. Using Autodock 4 and the Lamarckian genetic algorithm as a basis, this in-silico study intends to investigate the potential of active compounds found in cinnamon and their role as 4IBM protein inhibitors for therapy in type 2 diabetes mellitus. The binding energy ranged from -7.95 to -6.15 kcal/mol, according to docking data, with the compound epicatechin having the lowest binding energy and an inhibitory constant of 7.80. Further investigation into the active ingredients in cinnamon and their potential use in the treatment of diabetes mellitus can be based on the findings of this study.